Compare Docusign Inc (DOCU) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Docusign Inc vs GSK plc — how do they compare? Docusign Inc trades at $70.2 (market cap $13.35B), while GSK plc trades at $46.59 (market cap $91.88B). The key difference: GSK plc is far larger — about 6.9× Docusign Inc's market cap, and GSK plc pays a 3.9% dividend while Docusign Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Docusign Inc for 71 Days and GSK plc for 93 Days on average.
| DOCU | GSK | |
|---|---|---|
Market Cap | $13.35B | $91.88B |
Volume | 3,158,858 | 7,730,529 |
Sector | Technology | Health |
52-Week High | $73.14 | $61.18 |
52-Week Low | $41.75 | $43.24 |
Typical Hold Time | 71 Days | 93 Days |
Enterprise Value | $12.76B | $111.88B |
Dividend Yield | — | 3.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOCU trades at $70.08, up 1.71% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported robust revenue growth to $2.98 billion in 2025, with net income surging to $1.07 billion, though cash flow turned negative. Recent news highlights AI integration in contract processing and leadership in workflow software.
Outlook remains positive with continued earnings momentum and AI-driven growth, but risks include insider selling and competitive pressures. The stock offers growth potential but requires monitoring of cash flow trends and market saturation in e-signature adoption.
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
